C4 Therapeutics Inc
NASDAQ:CCCC
Income Statement
Earnings Waterfall
C4 Therapeutics Inc
Income Statement
C4 Therapeutics Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
2
|
3
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
34
N/A
|
34
+0%
|
46
+35%
|
46
+0%
|
50
+9%
|
48
-3%
|
31
-36%
|
27
-13%
|
16
-41%
|
20
+27%
|
21
+2%
|
20
-3%
|
29
+47%
|
34
+15%
|
36
+6%
|
40
+12%
|
34
-14%
|
30
-12%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(114)
|
(120)
|
(128)
|
(139)
|
(148)
|
(155)
|
(161)
|
(162)
|
(161)
|
(160)
|
(160)
|
(153)
|
(146)
|
(151)
|
(153)
|
(156)
|
(158)
|
(149)
|
|
| Selling, General & Administrative |
(26)
|
(31)
|
(33)
|
(39)
|
(40)
|
(41)
|
(43)
|
(41)
|
(41)
|
(42)
|
(42)
|
(41)
|
(41)
|
(42)
|
(42)
|
(41)
|
(40)
|
(37)
|
|
| Research & Development |
(88)
|
(89)
|
(95)
|
(100)
|
(108)
|
(114)
|
(118)
|
(121)
|
(119)
|
(118)
|
(118)
|
(111)
|
(105)
|
(109)
|
(111)
|
(115)
|
(118)
|
(112)
|
|
| Operating Income |
(80)
N/A
|
(86)
-7%
|
(82)
+4%
|
(93)
-13%
|
(98)
-6%
|
(107)
-8%
|
(130)
-22%
|
(134)
-4%
|
(145)
-8%
|
(140)
+3%
|
(139)
+1%
|
(133)
+5%
|
(116)
+12%
|
(117)
0%
|
(117)
0%
|
(117)
+1%
|
(124)
-6%
|
(119)
+4%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(7)
|
(4)
|
(2)
|
(2)
|
(1)
|
(0)
|
1
|
3
|
5
|
7
|
8
|
11
|
13
|
14
|
14
|
13
|
12
|
11
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
(3)
|
(3)
|
(2)
|
(2)
|
0
|
0
|
(11)
|
|
| Pre-Tax Income |
(87)
N/A
|
(90)
-3%
|
(84)
+7%
|
(95)
-13%
|
(99)
-5%
|
(107)
-7%
|
(128)
-20%
|
(131)
-2%
|
(140)
-6%
|
(134)
+4%
|
(131)
+2%
|
(125)
+5%
|
(107)
+15%
|
(105)
+1%
|
(105)
+0%
|
(103)
+2%
|
(111)
-8%
|
(119)
-7%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1)
|
(1)
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Income from Continuing Operations |
(87)
|
(90)
|
(84)
|
(95)
|
(99)
|
(107)
|
(128)
|
(131)
|
(140)
|
(135)
|
(132)
|
(126)
|
(108)
|
(105)
|
(105)
|
(103)
|
(112)
|
(119)
|
|
| Net Income (Common) |
(82)
N/A
|
(80)
+3%
|
(84)
-5%
|
(95)
-13%
|
(99)
-5%
|
(107)
-7%
|
(128)
-20%
|
(131)
-2%
|
(140)
-6%
|
(135)
+4%
|
(132)
+2%
|
(126)
+5%
|
(108)
+14%
|
(105)
+2%
|
(105)
+0%
|
(103)
+2%
|
(112)
-8%
|
(119)
-7%
|
|
| EPS (Diluted) |
-1.87
N/A
|
-1.64
+12%
|
-1.82
-11%
|
-1.94
-7%
|
-2.04
-5%
|
-2.18
-7%
|
-2.62
-20%
|
-2.68
-2%
|
-2.85
-6%
|
-2.75
+4%
|
-2.67
+3%
|
-1.84
+31%
|
-1.56
+15%
|
-1.51
+3%
|
-1.52
-1%
|
-1.47
+3%
|
-1.58
-7%
|
-1.64
-4%
|
|